The marketing authorisation for Avaglim has been withdrawn for safety reasons following a decision by the European Commission.
Therapeutic Indication
AVAGLIM is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control on optimal dosage of sulphonylurea monotherapy, and for whom metformin is inappropriate because of contraindication or intolerance.
Therapeutic Area (MeSH)
ATC Code
A10BD04
ATC Item
N/A
Pharmacotherapeutic Group
Drugs used in diabetes
Active Substance (Summary)
INN / Common Names
EMA Name
Avaglim
Medicine Name
Avaglim
Aliases
N/ANo risk management plan link.
